

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Acanthosis, in nevoid melanoma, 244
- Acral lentiginous melanoma, **281–288**
 - differential diagnosis of, 284–286
 - epidemiology of, 281
 - gross pathology of, 281
 - histology of, 282–283
 - immunohistochemistry of, 283–284
 - key features of, 281
 - microscopic features of, 282–284
 - overview of, 281–282
 - prognosis of, 286–287
- Acral lentiginous nevi, versus acral lentiginous melanoma, 284–286
- Acral nevi, 230, 233–234, 236, 238–239
- Amelanotic blue nevi, 347, 349–350, 354
- Animal-type melanoma, 347
- Array competitive genomic hybridization, for melanoma gene identification, 336–337
- Array techniques, for melanoma gene identification, 336–338
- Asymmetry, in special-site nevi, 234, 238
- Attenuation, in nevoid melanoma, 244
- Atypical nevi. *See* Dysplastic nevi.
- Axilla, nevi of, 230–233, 236–239

B

- Benign acquired classic blue nevi, 345
- Biopsy
 - for nevoid melanoma, 251
 - melanocytic hyperplasia secondary to, 294
- Blue nevi and related tumors, **345–358**
 - clinical features of, 345–347
 - diagnosis of, 347–351
 - differential diagnosis of, 351–354
 - gross features of, 345–347
 - key features of, 346
 - microscopic features of, 347–351
 - overview of, 345
 - prognosis of, 354
 - variants of, 347
- BRAF mutations, in melanoma, 331–333, 337–338

Bread-loaf (transverse vertical) sections, for margin assessment, 289–290, 294–295
Breast, nevi of, 230–233, 236–239

C

Capsular nevi, versus metastatic melanoma, 305

Carcinomas

- versus acral lentiginous melanoma, 286
- versus desmoplastic melanoma, 326

Carney complex, blue nevi and, 347, 351

CDKN2A mutations, in melanoma, 334

Cellular blue nevi, 345, 347, 349, 352, 354–355

Cellular neurothekeomas, versus blue nevi, 353

Circumscription, in special-site nevi, 238

Clark's nevi. *See* Dysplastic nevi.

Clear cell sarcoma, versus blue nevi, 353–354

Combined blue nevi, 348–349

Common (Tieche-type) blue nevi, 348

Comparative genomic hybridization, for spitzoid neoplasms, 318–319

Compound congenital melanocytic nevi, 268–269

Compound dysplastic nevi, 272

Compound Spitz nevi, 313–314

Congenital melanocytic nevi, **267–280**

- classification of, 267
- diagnosis of, 272–276
- differential diagnosis of, 269–272
- gross features of, 267–268
- key features of, 268
- melanoma risk in, 267
- microscopic features of, 268–269
- overview of, 267
- prognosis of, 276–277
- staged excision of, 268
- versus dysplastic nevi, 262–263
- versus nevoid melanoma, 250–251

Crowded pattern, in special-site nevi, 231

Cyclins, in nevoid melanoma, 248

D

Deep penetrating nevi, 353, 355

Dendritic melanocytes, in blue nevi, 347–349

Dermal melanocytoses, 345

Dermal sclerosis, in Spitz nevi, 314

Dermal Spitz nevi, 313–314

Dermatofibromas, versus blue nevi, 352–354

Dermoepidermal junction, melanocyte proliferation at, in acral lentiginous melanoma, 282

Desmoplastic carcinomas, versus desmoplastic melanoma, 326

Desmoplastic melanoma, **321–330**

- clinical features of, 322
- diagnosis of, 326–327

- differential diagnosis of, 324–326
 - in congenital melanocytic nevi, 271–272
 - key features of, 321
 - microscopic features of, 322–324
 - overview of, 321
 - prognosis of, 327–328
 - versus blue nevi, 352, 354
- Drug-induced pigmentation, versus blue nevi, 352–353
- Dyshesive nests, in special-site nevi, 231, 233
- Dysplastic nevi, **255–265**
- clinical features of, 256–257
 - definition of, 255
 - diagnosis of, 260–262
 - differential diagnosis of, 262–264
 - gross features of, 256
 - immunohistochemistry in, 260
 - key features of, 255
 - microscopic features of, 256–260
 - prognosis of, 262
 - synonyms for, 255
 - treatment of, 262
 - versus congenital melanocytic nevi, 272
 - versus special-site nevi, 235–237
- Dysplastic nevus syndrome, 256

E

- Ear, nevi of, 233–234, 236
- En face sections, for margin assessment
- oblique, 291, 295
 - vertical, 290–291, 295
- Epidermal hyperplasia
- in Spitz nevi, 313
 - in spitzoid melanoma, 314
- Epithelioid blue nevi, 345, 347
- Epithelioid cytomorphology
- in desmoplastic melanoma, 322
 - in spitzoid melanoma, 314
- Excision
- for congenital melanocytic nevi, 268
 - for melanoma, margin assessment in, 289–300
- Expression microarray analysis, for melanoma gene identification, 336–337

F

- Familial atypical multiple mole melanoma syndrome, 256
- Fibromas, versus desmoplastic melanoma, 325–326
- Fibroplasia
- in dysplastic nevi, 256–257
 - in special-site nevi, 232–234
- Fibrosis, in desmoplastic melanoma, 322–323, 326–327

- Field effects, margin assessment and, 294
- Flexural nevi, 230–233, 236–239
- Fluorescence in situ hybridization
 - for melanoma, 339
 - for spitzoid neoplasms, 318–319
- Fried egg appearance, in blue nevi, 351
- Frozen sections
 - for margin assessment, 295–296
 - for sentinel lymph nodes, 302

G

- Genital nevi, 230–232, 235–236, 238–239
- gp100, antibody to, in nevoid melanoma, 247–249

H

- Hamartomas, melanocytic, 345, 348
- HMB45 antibody
 - for margin assessment, 297
 - for sentinel lymph nodes, 303–304
 - in acral lentiginous melanoma, 283–284, 286
 - in nevoid melanoma, 247–249
- HRAS mutations, in melanoma, 338–339
- Hyperchromasia, in nevoid melanoma, 246
- Hypergranulosis, in Spitz nevi, 313
- Hyperkeratosis, in Spitz nevi, 313
- Hyperpigmentation, postinflammatory, versus blue nevi, 352–353
- Hypomelanotic blue nevi, 354

I

- Immunohistochemistry
 - for acral lentiginous melanoma, 283–284
 - for dysplastic nevi, 260
 - for margin assessment, 296–297
 - for metastatic melanoma, 303–304
 - for nevoid melanoma, 247–250
 - for sentinel lymph nodes, 303–304
- In situ melanoma, margin assessment for, 292–293
- Intradermal component, of nevoid melanoma, 245–247
- Intradermal congenital melanocytic nevi, 268–269
- Invasive melanoma
 - desmoplastic, 327
 - margin assessment for, 294
- Ito, nevus of, 345

J

- Junctional congenital melanocytic nevi, 268–269
- Junctional Spitz nevi, 313–314

K

- Kamino bodies, in Spitz nevi, 313–314
- Ki-67
 - in acral lentiginous melanoma, 284, 286
 - in nevoid melanoma, 247–249

L

- Leiomyosarcomas, versus desmoplastic melanoma, 326
- Lentiginous, solar, margin assessment for, 294
- Lentiginous proliferation
 - in congenital melanocytic nevi, 273–274
 - in melanocytic nevi, 272
 - in special-site nevi, 238
- Lentigo maligna
 - desmoplastic melanoma with, 322
 - margin assessment for, 292–293
- Lichenoid reactions, margin assessment for, 294
- Lymph nodes, sentinel. *See* Sentinel lymph nodes.
- Lymphocytic aggregates, in desmoplastic melanoma, 323
- Lymphohistiocytic inflammatory infiltrate, in dysplastic nevi, 256

M

- Macrophages, versus metastatic melanoma, 304–305
- Malignant blue nevi, 347, 349–350, 355
- Malignant peripheral nerve sheath tumor, 326
- MANIAC acronym, for nevi, 233, 236
- Margin assessment, for melanoma, **289–300**
 - immunohistochemistry for, 296–297
 - methods of, 289–291
 - on sun-damaged skin, 291–296
 - overview of, 289
 - positive margin in, 292
- Maturation
 - in nevoid melanoma, 245–247
 - in special-site nevi, 239
- Melan-A/MART-1 antibody
 - for margin assessment, 296–297
 - for sentinel nodes, 303–304
- Melanocytic hyperplasia, secondary to previous biopsy, 294
- Melanocytomas, pigmented epithelioid, 345
- Melanoma
 - acral lentiginous, **281–288**
 - clinicopathologic variants of, 337
 - desmoplastic, 271–272, **321–330**
 - development of
 - from congenital melanocytic nevi, 267, 276–277
 - from special-site nevi, 237, 240
 - from spitzoid neoplasms, 319–320

Melanoma (*continued*)

- margin assessment for, **289–300**
- metastatic, 251, 347
- molecular aspects of, **331–343**
- nevroid, **243–253**, 269–270
- sentinel lymph nodes in, 252, **301–310**
- signaling pathways in, 331–335
- spitzoid, **311–320**
- versus dysplastic nevi, 262
- versus special-site nevi, 236
- Melanoma in situ, versus nevroid melanoma, 250–251
- Metallothionein, in nevroid melanoma, 248–249
- Metastatic melanoma, 347
 - to sentinel lymph nodes. *See* Sentinel lymph nodes.
 - versus nevroid melanoma, 251
- Mib1 antibody, in nevroid melanoma, 247–249
- Microarray analysis, for melanoma gene identification, 336–338
- Microphthalmia transcription factor
 - for margin assessment, 297
 - in dysplastic nevi, 260
- Milking nevi, 230–233, 236–239
- Mitogen-activated protein kinase, in melanoma, 331–333
- Mitoses
 - in acral lentiginous melanoma, 283
 - in atypical spitzoid neoplasm, 315
 - in blue nevi, 349, 354
 - in nevroid melanoma, 250
 - in special-site nevi, 239
 - in Spitz nevi, 314
- Moh surgery (n face oblique sections), for margin assessment, 291, 295
- Molecular pathology, of melanoma, **331–343**
 - histopathology and, 338–339
 - novel genes in, 336–338
 - overview of, 331
 - signature changes, 331–335
- Mongolian spot, 345
- Mushroom shape, in special-site nevi, 232
- Myoepitheliomas, versus blue nevi, 353–355
- Myxoid desmoplastic melanoma, 324

N

Necrosis

- in blue nevi, 349, 354
- in spitzoid melanoma, 314
- NEDD9 mutations, in melanoma, 337
- Nerve invasion, in desmoplastic melanoma, 323, 327
- Nested patterns
 - in acral lentiginous melanoma, 282–283
 - in acral lentiginous nevi, 284–286
 - in blue nevi, 349, 354
 - in congenital melanocytic nevi, 269

- in dysplastic nevi, 256–257
 - in nevoid melanoma, 245
 - in special-site nevi, 231–240
 - in Spitz nevi, 313
- Neurothekeomas, versus blue nevi, 354–355
- Neurotropism, of desmoplastic melanoma, 323, 327
- Nevi
- blue, **345–358**
 - congenital melanocytic, 250–251, **267–280**
 - dysplastic, 235–237, **255–265**, 272
 - of special sites, **229–242**
 - Spitz, **311–320**
- Nevoid melanoma, **243–253**
- diagnosis of, 251
 - differential diagnosis of, 250–251
 - gross features of, 244
 - immunohistochemistry of, 247–250
 - key features of, 244
 - microscopic features of, 244–247
 - prognosis of, 251–252
 - treatment of, 252
 - versus congenital melanocytic nevi, 269–270
- Nevus of Ito, 345
- Nevus of Ota, 345
- Nevus with architectural disorder. *See* Dysplastic nevi.
- NRAS mutations, in melanoma, 331–333, 337–338
- Nuclear atypia
- in blue nevi, 349–350
 - in desmoplastic melanoma, 323
 - in dysplastic nevi, 256, 258–260
 - in nevoid melanoma, 246
 - in special-site nevi, 239
 - in spitzoid melanoma, 314
- O**
- Ota, nevus of, 345
- P**
- p16 mutations, in melanoma, 248–249, 334–335
- p53 mutations, in melanoma, 335
- Paget disease, versus special-site nevi, 237
- Pagetoid spread
- in acral lentiginous melanoma, 282–283, 285
 - in congenital melanocytic nevi, 274
 - in dysplastic nevi, 260
 - in nevoid melanoma, 245
 - in special-site nevi, 234, 239
- Palmar nevi, 230, 233–234, 236, 238–239
- Pan-melanocytic cocktail, for sentinel lymph nodes, 303–304
- p14^{ARF} mutations, in melanoma, 335

Penis, nevi of, 230–232, 235–236, 238–239
Perineural invasion, in desmoplastic melanoma, 323
Pigmented epithelioid melanocytoma, 345, 348–349
PI3K-Akt signaling pathway, in melanoma, 333–334
Plantar nevi, 230, 233–234, 236, 238–239
Pleomorphic sarcoma, versus desmoplastic melanoma, 326
Pleomorphism, in congenital melanocytic nevi, 271
Positive surgical margin, definition of, 292
Proliferation, in special-site nevi, 232–233
Proliferative nodules, in congenital melanocytic nevi, 274–275
PTEN mutations, in melanoma, 333–334

R

RAS mutations, in melanoma, 331–334
Recurrent nevi
 congenital, 274–275
 versus dysplastic nevi, 263–264
Reed's nevi, 312–313
Regressing nevi, versus blue nevi, 352
Rete ridges
 in dysplastic nevi, 256, 260
 in special-site nevi, 233–234, 238

S

S-100 protein
 for margin assessment, 297
 for sentinel lymph nodes, 303–304
 in acral lentiginous melanoma, 283–284
Sarcomas
 versus blue nevi, 353
 versus desmoplastic melanoma, 326
Sarcomatoid carcinoma, versus desmoplastic melanoma, 326
Scalp, nevi of, 230, 234–235, 237–239
Scars
 versus blue nevi, 352
 versus desmoplastic melanoma, 325–326
Sclerosing blue nevi, 349, 354
Sclerosing melanocytic nevi, versus desmoplastic melanoma, 324–325
Sclerosing mucinous blue nevi, 349
Sclerosing variant of blue nevi, 347
Senescence, in melanoma, 335
Sentinel lymph nodes, in melanoma, **301–310**
 biopsy of, 252
 diagnosis of, 305–306
 differential diagnosis of, 304–305
 gross features of, 301–302
 microscopic features of, 302–304
 overview of, 301
 prognosis of, 306–307
Solar lentigines, margin assessment for, 294

Solar melanocytic hyperplasia, margin assessment for, 293

Special sites, nevi of, **229–242**

- acral, 230, 233–234, 236, 238–239
- clinical appearance of, 230–231
- diagnosis of, 235–239
- differential diagnosis of, 237
- etiology of, 229
- flexural, 230–233, 236–239
- genital, 230–232, 235–236, 238–239
- gross features of, 230–231
- key features of, 230
- microscopic features of, 231–235
- overview of, 229
- prognosis of, 237, 240
- scalp, 230, 234–235, 237–239

Spindle cells

- in atypical spitzoid neoplasm, 314–315
- in desmoplastic melanoma, 322, 326
- in Spitz nevi, 314
- proliferation of, versus desmoplastic melanoma, 325–326

Spitz nevi, **311–320**

- differential diagnosis of, 316–319
- gross features of, 312–313
- key features of, 312
- microscopic features of, 313–316
- overview of, 311–312
- prognosis for, 319–320

Spitzoid melanoma, **311–320**

- differential diagnosis of, 316–319
- gross features of, 312–313
- key features of, 312
- microscopic features of, 313–316
- overview of, 311–312
- prognosis for, 319–320

Spitzoid neoplasms, atypical, **311–320**

- differential diagnosis of, 316–319
- gross features of, 312–313
- key features of, 312
- microscopic features of, 313–316
- overview of, 311–312
- prognosis for, 319–320

Stromal reaction, in special-site nevi, 234

Sun-damaged skin, margin assessment for, 291–296

T

Transverse (bread-loaf) vertical sections, for margin assessment, 289–290, 294–295

U

Ulceration

- in atypical spitzoid neoplasms, 315
- in nevoid melanoma, 245

V

Verrucous appearance, in nevoid melanoma, 244

Vulva, nevi of, 230–232, 235–236, 238–239

W

WNT5A mutations, in melanoma, 339

WT-1, in nevoid melanoma, 248–249